Akshaya Bio Inc. Chimigen® Technology-Based Molecular Vaccines
InnovationScan
November, 2013 Akshaya Bio Inc.
…..…………..focus is on vaccines
1
Akshaya Bio Inc. Outline • The Company Management Research Team Collaborators
• Chimigen® Platform Technology Unique Features Product Pipeline Status • Highlights • Contacts Akshaya Bio Inc.
…..…………..focus is on vaccines
2
Akshaya Bio Inc.- Current • Based in Edmonton, Alberta 8223 Roper Road Currently a team of Nine, Eight Researchers (7 Ph.Ds, 1 B.Sc. 1 MBA)
• Founded in 2010 Dendritic cell receptor-targeted vaccines Proprietary technology • 16 issued patents • 32 patents pending worldwide Acquired Chimigen® Technology from Paladin Labs Inc. and ViRexx Medical Corp., (TSX, AMEX)
• External Partners in Research and Development NRC-IRAP, CHTD, AITF, Gates Foundation
• Unique technology platform Improved antigen presentation
• Rich Product Pipeline HBV, HCV, HIV, Cancer, Malaria, Biodefense, Influenza, Akshaya Bio Inc.
…..…………..focus is on vaccines
3
Management Team • Satish Chandran, Ph.D • Chief Executive Officer • Rajan George, M.Sc, Ph.D • President and Chief Scientific Officer • Bruce Hirsche, QC • General & Intellectual Property Counsel • Rohit George, BA, MBA • Business Operations Akshaya Bio Inc.
…..…………..focus is on vaccines
4
Research Team • Allan Ma, Ph.D • Senior Scientist, Virologist • Dakun Wang, Ph.D • Senior Scientist, Immunologist • Yun Xia, Ph.D • Cell Biologist/Immunologist • Morris Kostiuk, Ph.D • Biochemist/Molecular Biologist • Gina Thede, Ph.D • Biochemist/Molecular Biologist • Hue Anh Luu, B.Sc • Technologist Akshaya Bio Inc.
…..…………..focus is on vaccines
5
Collaborators •
•
•
• • • • •
NRC/IRAP – Eric Swanson, Ph.D Nuron Biotech – HBV Vaccine License – HCV Vaccine License Option University of Alberta- HBV & HCV Clinical Research – Klaus Gutfreund, M.D, Assoc. Professor, Medicine, U of A – Mang Ma, M.D, Assoc. Professor, Medicine, U of A VIDO/InterVac-Immunology in Animals – Qiang Li, Ph.D NRC-NINT-Nanoparticles – Nils Peterson, Ph.D CHTD/Gates Foundation DRDC Suffield – Les Nagata, Ph.D (Head Biotechnology Section) NIH – HBV & HCV
Akshaya Bio Inc.
…..…………..focus is on vaccines
6
Chimigen® Platform Technology
Novel Approach to an Established Concept
Dendritic Cell Receptor-Targeted Vaccines
Akshaya Bio Inc.
…..…………..focus is on vaccines
7
Chimigen®- A Platform Technology Chimigen® Recombinant Molecule 6xHis
6xHis Antigen
Antigen
CHO
IRD CHO
Peptide Linker Portion of CH 1
S-S
Hinge Region
S-S S S
CHO
CH2 S S CCH2 H2
Xenotypic (Murine) Fc
CHO
TBD
SS SS
C H3
CH3
Peptide
Strong Intellectual Property Position 16 Issued Patents, 32 Patent Applications Pending worldwide Akshaya Bio Inc.
…..…………..focus is on vaccines
8
Chimigen®- A Platform Technology • Characteristics of both Antigen (Ag) and Antibody (Ab) • Xenotypic (foreign) Ab fragment makes whole molecule “foreign” & thus more immunogenic • Adaptable platform – Adaptable to disease-specific multiple molecular antigenic epitopes – HBV, HCV, HIV, Biodefense Applications (Alphaviruses), Pandemic Preparedness (H5N1, H1N1), Malaria, Cancer etc.
• Designed to generate broad immune responses – Cellular (Class I)- critical to clear virus infected & cancer cells – Humoral (Class II)- Antibodies
• Potential use for both Prophylactic & Therapeutic Vaccines Akshaya Bio Inc.
…..…………..focus is on vaccines
9
Chimigen®- A Platform Technology •
•
•
• •
Effective at low doses (µg) – Targets multiple cell types relevant to immune activation – Targets multiple specific receptors on Antigen Presenting Cells • Dendritic Cells (Fcy, Lectin Receptors) Minimal safety concerns – Utilizes classical antigen presentation pathway – No added adjuvant • Eliminates many adverse events • Eliminates T cell sequestration, dysfunction & deletion (Nat. Med. 2013, Lu. et al) Ease of production and scalability – Utilizes insect cell-based production • Increased antigenicity through production of the chimeric molecule in Insect Cells • Imparts non-mammalian glycosolation; Highly immunogenic Established purification systems Binding and uptake through Fc and Lectin receptors
Akshaya Bio Inc.
…..…………..focus is on vaccines
10
Product Pipeline & Status • HBV Therapeutic/Prophylactic Vaccine • Preclinical completed (Licensed to Nuron, co-development)
• HCV Therapeutic/Prophylactic Vaccine • Preclinical (Nuron co-development, option to license)
• HIV Prophylactic/Therapeutic Vaccine • Discovery (CHTD-NRC-IRAP)
• Cancer Vaccine • Discovery
• Malaria • Late discovery stage (Gates Foundation); ready for animal studies
• Biodefense and Pandemic Applications • Alphavirus (WEEV) Vaccine, Discovery/Preclinical
• Influenza H5 & H1 • Pre-clinical
Akshaya Bio Inc.
…..…………..focus is on vaccines
11
Akshaya’s Competitive Advantages • Meets major unmet needs No vaccine/therapy available • Efficacy, it works Proof of Concept established HBV Chronic Carriers Breaking Tolerance • No Adjuvant Eliminates majority of the adverse reactions The Scare Factor Eliminates production of “dysfunctional CTLs” • Re-educating the immune system Uses Dendritic Cell Receptor Natural endogenous process for uptake and presentation of antigens & induction of broad immune responses
Akshaya Bio Inc.
…..…………..focus is on vaccines
12
Chimigen® Vaccine Highlights Highlights • Versatile, Adaptable Platform • Dendritic Cell Receptor-Targeted Vaccines • Generates broad immune responses – Cellular (Class I)- critical to clear virus infected & cancer cells – Humoral (Class II)- Abs- Helps CTLs • Proof of principle established with Chimigen® HBV Therapeutic Vaccine • Potential use for both Prophylactic & Therapeutic Vaccines • Strong Intellectual Property Position Akshaya Bio Inc.
…..…………..focus is on vaccines
13
Contacts • Satish Chandran, Ph.D
Rajan George, M.Sc, Ph.D
•
Chief Executive Officer
President & Chief Scientific Officer
• • • •
8223 Roper Road Edmonton Alberta, T6E 6S4 Canada
8223 Roper Road Edmonton Alberta, T6E 6S4 Canada
•
Mobile: 215 896 3392
•
Email:
[email protected]
Telephone: 780 989 6705 Mobile: 780 493 1706 Email:
[email protected] Web: www.akshayabio.com
•
Web: www.akshayabio.com
Akshaya Bio Inc.
…..…………..focus is on vaccines
14
Akshaya Bio Inc.
Thank You…….
Akshaya Bio Inc.
…..…………..focus is on vaccines
15
